When will evantumumab be launched in China?

Amivantamab (amivantamab-vmjw) is the world's first EGFR/cMET dual-antibody drug approved for marketing. The drug, developed by Johnson & Johnson, is mainly used to treat patients with non-small cell lung cancer (NSCLC), especially those with advanced or metastatic NSCLC who have progressed after receiving platinum-based chemotherapy and carry EGFR exon 20 insertion mutations. At present, according to our understanding, evantumumab has not yet been launched in China. Since the time to market of a drug may be affected by multiple factors, such as clinical trial progress, regulatory approval, etc., it is impossible to accurately predict its time to market.

The recommended dose for phase 2 clinical trials of evantumumab was selected based on serum EGFR and MET target saturations and the established preclinical concentration of 168ug/mL. At doses above 700 mg, EGFR and methionine cycle indicators reach saturation. Dosage is determined by body weight, using population dynamics to minimize pharmacokinetic variability, resulting in a recommended dose of 1400 mg for body weight ≥80 kg and 1050 mg for body weight <80 kg. The distribution and clearance of evantumumab increased as body weight increased, which was attributed to the two-stage weight-based dosing.

This drug is only available with a prescription. Treatment with evantumumab should be initiated and supervised by a physician experienced in the use of cancer drugs and in an environment where any infusion-related side effects can be controlled. Evantumumab is given as an intravenous infusion (drip). Dosing is divided into two consecutive days for the first week, then once a week for the next three weeks, and once every two weeks thereafter. Continue treatment until the disease worsens or the side effects become too severe. Treatment should be stopped temporarily or permanently, and subsequent doses can be reduced if the patient experiences certain side effects.